Tracking Antimicrobial Use in Food-Producing Animals
- The Reagan-Udall Foundation for the FDA is partnering with the FDA's Center for Veterinary Medicine (CVM) to explore the development of a public-private partnership framework for collecting and analyzing real-world data regarding antimicrobial use (AMU) in food-producing animals.
- The Foundation facilitated a series of working sessions with stakeholders to gather input on the benefits, costs, and challenges of creating and maintaining a voluntary AMU data repository that could enhance understanding of how antimicrobials are used in animals and support antimicrobial stewardship. These discussions with stakeholders from animal agriculture, veterinary, public health organizations, and other key representatives were summarized in a report entitled, “Exploring the Potential for A Public-Private Partnership to Support the Tracking and Monitoring of Antimicrobial Use in Food-Producing Animals.”
- For more information, contact Dr. Amar Bhat of the FDA Foundation.
Summary Report: Establishing a Draft Framework for a Public-Private Partnership to Support the Tracking of Antimicrobial Use in Food-Producing Animals
Antimicrobial resistance (AMR) is recognized as a growing global threat requiring action in new product research and development and greater stewardship of antimicrobial use (AMU) in human and animal health.
The FDA Foundation, working with the FDA's Center for Veterinary Medicine and the food-animal producing industry, outlines a public-private partnership framework and develops a long-term strategy for implementing an infrastructure for collecting AMU data in animals from diverse veterinary and animal production sectors within the United States.
FDA is seeking public comment on this report, and the potential framework it describes. To submit your comments click here. Deadline for comments is October 31, 2023.
This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an award of $65,329 in federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit FDA.gov.